Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zinc Supplementation in SSRI-treated MDD
NCT04482296Completed
- Sponsor
- Bangabandhu Sheikh Mujib Medical University
- Start
- Sep 2019
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in major depressive disorder (MDD) comparing SSRI with placebo with SSRI with zinc sulfate (2 arms). Primary endpoint: Serum Zinc Level at 8 weeks. Started Sep 2019; status: completed.
02
Drugs
zinc
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04482296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04482296.